Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free NKGNW Stock Alerts

NKGen Biotech (NKGNW) Competitors

$0.0003 0.00 (0.00%)
As of 08/14/2026
Compare

NKGNW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NKGen Biotech stock or one of its competitors? NKGen Biotech's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NKGen Biotech compare to Alvotech?

NKGen Biotech (NASDAQ:NKGNW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Alvotech had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for NKGen Biotech. Alvotech's average media sentiment score of 0.93 beat NKGen Biotech's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
NKGen Biotech Neutral
Alvotech Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats NKGen Biotech on 3 of the 3 factors compared between the two stocks.

How does NKGen Biotech compare to Apollomics?

Apollomics (NASDAQ:APLMW) and NKGen Biotech (NASDAQ:NKGNW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
NKGen BiotechN/AN/AN/AN/AN/A

In the previous week, Apollomics had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Apollomics and 0 mentions for NKGen Biotech. Apollomics' average media sentiment score of 0.29 beat NKGen Biotech's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Neutral
NKGen Biotech Neutral

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
NKGen Biotech N/A N/A N/A

Summary

Apollomics beats NKGen Biotech on 3 of the 3 factors compared between the two stocks.

How does NKGen Biotech compare to Aravive?

NKGen Biotech (NASDAQ:NKGNW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Aravive Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aravive beats NKGen Biotech on 2 of the 2 factors compared between the two stocks.

How does NKGen Biotech compare to bioAffinity Technologies?

NKGen Biotech (NASDAQ:NKGNW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

In the previous week, bioAffinity Technologies had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for NKGen Biotech. bioAffinity Technologies' average media sentiment score of 0.63 beat NKGen Biotech's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
NKGen Biotech Neutral
bioAffinity Technologies Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

Summary

bioAffinity Technologies beats NKGen Biotech on 3 of the 3 factors compared between the two stocks.

How does NKGen Biotech compare to BioVie?

BioVie (NASDAQ:BIVIW) and NKGen Biotech (NASDAQ:NKGNW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
NKGen Biotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
NKGen BiotechN/AN/AN/AN/AN/A

In the previous week, BioVie had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for BioVie and 0 mentions for NKGen Biotech. BioVie's average media sentiment score of 0.82 beat NKGen Biotech's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Positive
NKGen Biotech Neutral

Summary

BioVie beats NKGen Biotech on 2 of the 2 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGNW vs. The Competition

Export
MetricNKGen BiotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.74B$7.03B$13.06B
Dividend YieldN/A3.69%2.56%10.62%
P/E RatioN/A11.49270.8525.39
Price / SalesN/A1,303.47607.8392.50
Price / CashN/A45.1128.8738.47
Price / BookN/A17.1711.096.51
Net IncomeN/A-$13.18M$3.45B$347.22M
7 Day PerformanceN/A1.53%0.74%1.51%
1 Month PerformanceN/A2.99%2.15%2.74%
1 Year PerformanceN/A56.69%63.00%21.07%

NKGen Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGNW
NKGen Biotech
N/A$0.00
flat		N/AN/A$0.00N/AN/A63
ALVOW
Alvotech
N/A$0.15
flat		N/A-83.5%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
flat		N/A-19.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.08
+9.1%		N/AN/A$0.00$5.61MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NKGNW) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel